Lilly Completes Centessa Deal to Accelerate Treatments for Narcolepsy and Sleep-Wake Disorders
INDIANAPOLIS, June 24, 2026 Eli Lilly and Company announced the successful completion of its acquisition of Centessa Pharmaceuticals plc,...
M&A
Advertisement
GSK and Spero Secure FDA Nod for First Oral Carbapenem
LONDON, United Kingdom, June 18, 2026 GSK plc and Spero Therapeutics have achieved a major milestone in the fight...
Biogen Signs Landmark RayThera Acquisition Worth Up to $1 Billion
CAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 Biogen Inc. has announced a strategic agreement to acquire RayThera Inc....
Simulations Plus to Join Altaris in $375M Acquisition Deal
RESEARCH TRIANGLE PARK, N.C., June 16, 2026 Simulations Plus, a global leader in model-informed and AI-accelerated drug development software,...
AlzeCure and Eli Lilly Partner on Alzheimer’s Drug ACD680
STOCKHOLM, Sweden, June 9, 2026 AlzeCure Pharma announced a global collaboration and out-licensing agreement with Eli Lilly and Company...
Advertisements
Novanta Acquires Riverpoint Medical in $1.45 Billion Deal
BOSTON, Massachusetts, USA – June 9, 2026 Novanta Inc. has announced a definitive agreement to acquire Riverpoint Medical in...
Innovent’s IBI343 Shows Strong Efficacy in Phase III Study, Eyes Regulatory Approval
SAN FRANCISCO and SUZHOU, China, June 4, 2026 Innovent Biologics has announced a major breakthrough in precision oncology as...
CytomX and Regeneron Expand $4B Cancer Immunotherapy Alliance
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 CytomX Therapeutics has announced a significant expansion of its strategic research...
Travere Licenses Civorebrutinib in $1.14B Kidney Disease Deal
SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Advertisement
